Celgene International SA rl, a wholly owned subsidiary of Celgene Corporation , today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for continuous oral treatment with REVLIMIDA in adult patients with previously untreated multiple myeloma who are not eligible for stem cell transplantation. "The positive opinion for REVLIMID for the continuous treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant is a significant step towards bringing a new therapy that could extend the time patients live without their disease progressing."
http://ift.tt/1wtxrMY
http://ift.tt/1wtxrMY
No comments:
Post a Comment